Navigation Links
ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine

TA's Annual Report on Form 10-K for the year ended December 31, 2006 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007.

CONTACT: Vince Anido, Ph.D., +1-949-788-5311, , orLauren Silvernail, +1-949-788-5302, , both ofISTA Pharmaceuticals; or investors, Juliane Snowden, ,or Nicki Kahner, . or Media, Jason Farber,, or Kristin Faucette, , all ofBurns McClellan, +1-212-213-0006, for ISTA Pharmaceuticals vanido@istavision.com lsilvernail@istavision.com jsnowden@burnsmc.com nkahner@burnsmc.com jfarber@burnsmc.com kfaucette@burnsmc.com

Web site: http://www.istavision.com/

Ticker Symbol: (NASDAQ-NMS:ISTA)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

Post Your Comments:
(Date:11/25/2009)...PRNewswire/ -- BioTrends Research Group, Inc. rele... report, the first in a multi-phase syndicated m...ocor Ortho-Biotech,s Stelara, from product launch ...h wave of the report provides quantitative informa... information from a subset of 20. The reports ass...
(Date:11/25/2009)...ov. 25 Remedium Technol...ike foam that stops severe bleeding, won first pri... category of the Global Security Challenge 2009, c...om more than 100 entries from around the world, Re...ecurity Summit conference held at the London Schoo...
(Date:11/25/2009)..., Nov. 25 /PRNewswire-Asia-FirstCall/ -- China Sky...e Company") (Nasdaq: CSKI ), a,leading fully inte...cing,over-the-counter drugs in the People,s Republ...any recently passed the Chinese National Institute...Products ("ICPBP") examination,for two of its new ...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Sharp HealthCare and Anakam 28R 29 Partner to Protect Patients Health Information 49971 1Sharp HealthCare and Anakam 28R 29 Partner to Protect Patients Health Information 49971 2Sharp HealthCare and Anakam 28R 29 Partner to Protect Patients Health Information 49971 3Nations Staff RNs Call on Congress to Implement Public Health Care Option 49966 1Nations Staff RNs Call on Congress to Implement Public Health Care Option 49966 2Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 1Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 2Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 3Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 4Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 5
..., ATLANTA, April 9, 2008 Dutch biotechnology,co...undation and the South,African Tuberculosis Vaccin... immunology data from a Phase I Ad35 tuberculosis ...es for the World" conference (Atlanta,Georgia, Apr...er, South,Africa and launched in May 2007, is the ...
...Selective Kinase Inhibitor Phase 1 Trial in Advanc... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stag...or the treatment of cancer and inflammatory diseas...1, dose-escalation study for its,selective kinase ... Dr.,Wells Messersmith, University of Colorado Can...
Other Medicine Technology:Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 2Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 3Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 4Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 5Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 6EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 2EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 4
(Date:11/27/2009)...ed medical, economic burdens, study predicts , ...umber of people with diabetes in the United States...ew study predicts. , That would bring the total...ease, up from 23.7 million today. , , At the sam...will triple, the study also warns, rising from an ...
(Date:11/27/2009)...rpose bilingual coloring books designed for childr...community to educate - inform parents and children... to Dinosuars to ABC,S and a host of other topics....) November 27, 2009 -- Today’s children have...busy any hour of the day, but one of the oldest an...
(Date:11/26/2009)...ewswire/ -- With cold and flu season upon us, it,s... to control the spread of infections and avoid ill...eep ourselves healthy, but to avoid transmitting i..., CIC (certified in infection-control), nursing di...th at Hospital for Special Surgery (HSS) in Manhat...
(Date:11/26/2009)...rathiomolybdate (TM) has been shown in studies to ... disease caused by an overload of copper, and cert...ittle, however, is known about how the drug works ...thwestern University researchers now has provided ...e of TM bound to copper-loaded metallochaperones. ...
(Date:11/26/2009)...letters from the North Pole, Textsanta.net lets pa...Santa , North Pole, AK (P...ciencies at the North Pole Santa Claus has added S...he globe informed of his Christmas progress at the...epartment have identified a large and growing perc...
Breaking Medicine News(10 mins):Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...ial result it is said that the dietary supplement ...g is used as an alternative to reduce cholesterol....and sometimes from beeswax, wheat germ and rice br...ity of Cologne, Germany. The drug contains alcoho...
... of obese individuals expressed that they would ra...g fat//. The following is the result of an online ...y and Obesity at Yale. The 4,000 respondents...essed, or become alcoholic rather than be obese. F...
... that cardiovascular clinical trials published bet...ng on whether they were funded by for-profit //org...e were the finding of a study in the May 17 issue ... (FP) organizations were more likely to report pos...
...Research Organization (ISRO) announced expansion o... more speciality hospitals in the country.// Manip... Delhi, Venkatrao Dawle Medical Foundation in Maha...rimental basis, is aimed at linking remote or rura...
...archers at the University of Pennsylvania and Temp... 2 (PAI-2) plays an important role in diseases of ...and the tissue covering the eyes.// The researche...e for Cancer Research at Temple University (http:/...
...found a link between the signaling pathways in the...ion between the immune and the nervous system.// T...for a potential HIV treatment that could effective...of Pennsylvania appears in the Proceedings of the ...
Other Medicine News:Health News:Fat People Claim That They Would Give Their Limb Or Life Rather Than Being Fat 2Health News:Results of Clinical Trials Vary According to Source of Funding 2Health News:ISRO To Expand Telemedicine Network, 4 Speciality Hospitals To Be Included 2Health News:PAI-2 Plays a Pivotal Role in Eye Infections 2Health News:Link Between Immune System And Nervous System 2
Mayo scissors
Straight scissors
Reddick/Saye Needle Holder, Straight
MultAcoice™ Biopsy Forceps
Medicine Products: